6.42
-0.16(-2.43%)
Currency In USD
| Previous Close | 6.58 |
| Open | 6.5 |
| Day High | 6.67 |
| Day Low | 6.36 |
| 52-Week High | 7.32 |
| 52-Week Low | 3.93 |
| Volume | 887,857 |
| Average Volume | 1.54M |
| Market Cap | 328.43M |
| PE | -10.19 |
| EPS | -0.63 |
| Moving Average 50 Days | 5.31 |
| Moving Average 200 Days | 5.65 |
| Change | -0.16 |
If you invested $1000 in Abeona Therapeutics Inc. (ABEO) 10 years ago, it would be worth $28.57 as of May 25, 2025 at a share price of $6.42. Whereas If you bought $1000 worth of Abeona Therapeutics Inc. (ABEO) shares 5 years ago, it would be worth $84.2 as of May 25, 2025 at a share price of $6.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire Inc.
May 14, 2025 11:30 AM GMT
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -- Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is read
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
GlobeNewswire Inc.
May 14, 2025 11:30 AM GMT
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is rea
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
GlobeNewswire Inc.
May 12, 2025 11:30 AM GMT
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $15